MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Device-detected atrial fibrillation

Search medical newsFind research, conditions and clinical updates
  • Home
  • Device-detected atrial fibrillation
Win Ratio Analysis Confirms No Net Benefit for Anticoagulation in Device-Detected Atrial Fibrillation
Posted inCardiology news

Win Ratio Analysis Confirms No Net Benefit for Anticoagulation in Device-Detected Atrial Fibrillation

Posted by By MedXY 01/03/2026
A hierarchical win ratio analysis of the NOAH-AFNET 6 trial confirms that edoxaban does not provide a net clinical benefit over no anticoagulation in patients with device-detected atrial fibrillation, primarily due to the balance between low stroke rates and significant bleeding risks.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • The Global Physical Literacy (GloPL) Action Framework: Consensus Process and Practical Recommendations
  • Aligning Rehabilitation Priorities to Enhance Home and Work Functioning in Low Back Pain: Insights from a Stakeholder-Driven Group Concept Mapping Study
  • Enhancing Diagnostic Confidence in Endodontics: Patient Perspectives on Cone-Beam Computed Tomography and Radiation Awareness
  • Empirical Tuberculosis Treatment in Infants Living with HIV Hospitalised with Severe Pneumonia in Africa (EMPIRICAL): A Comprehensive Review of a Multicentre Randomised Controlled Trial
  • Elevated Mental Health Diagnosis Prevalence Among Children With Complex and Chronic Medical Conditions: Implications for Screening and Equity
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top